Table 1.
Summary of studies on the unanalyzed cytokines.
| Cytokine | Sample type | Sample size (n) | Results | References | |
|---|---|---|---|---|---|
| Case | Control | ||||
| IL-6sR | Plasma | 25 | 25 | NA | (48) |
| Eotaxin-2 | Plasma | 25 | 25 | NA | (48) |
| Eotaxin-3 | Serum | 30 | 29 | The concentration of Eotaxin-3 in ASD group was significantly decreased | (54) |
| Fractalkine | Plasma | 87 | 41 | NA | (78) |
| Plasma | 99 | 40 | The concentration of Fractalkine in ASD group was significantly decreased | (44) | |
| IFNα2 | Plasma | 28 | 28 | NA | (40) |
| IL-1 | Serum | 77 | 77 | The concentration of IL-1 in ASD group was significantly increased | (27) |
| Serum | 23 | 33 | NA | (22) | |
| MCP-3 | Plasma | 99 | 40 | The concentration of MCP-3 in ASD group was significantly decreased | (44) |
| Plasma | 28 | 28 | NA | (40) | |
| MIP-1δ | Plasma | 25 | 25 | NA | (48) |
| TNF sRI | Plasma | 25 | 25 | NA | (48) |
| TNF sRII | Plasma | 25 | 25 | NA | (48) |
| EGFR | Plasma | 33 | 34 | The concentration of EGFR in ASD group was significantly increased | (53) |
| HB-EGF | Serum | 30 | 29 | The concentration of HB-EGF in ASD group was significantly decreased | (54) |
| NGF | Plasma | 21 | 16 | The concentration of NGF in ASD group was significantly increased | (77) |
| Plasma | 28 | 28 | NA | (40) | |
| IL-17F | Serum | 32 | 28 | NA | (76) |
| IL-22 | Serum | 32 | 28 | NA | (76) |
| IL-21 | Serum | 32 | 28 | NA | (76) |
| GRO-α | Serum | 65 | 30 | NA | (72) |
| Plasma | 28 | 28 | The concentration of GRO-α in ASD group was significantly increased | (40) | |
| Basic FGF | Serum | 12 | 8 | NA | (69) |
| M-CSF | Plasma | 25 | 25 | NA | (48) |
| Plasma | 28 | 28 | NA | (40) | |
| PDGF-AA | Serum | 31 | 31 | NA | (36) |
| PDGF-AB | Serum | 31 | 31 | NA | (36) |
| ENA-78 | Serum | 62 | 62 | The concentration of ENA-78 in ASD group was significantly increased | (59) |
| Serum | 21 | 15 | NA | (41) | |
| IL-33 | Plasma | 30 | 18 | NA | (56) |
| Serum | 38 | 13 | NA | (61) | |
| ST2 | Plasma | 30 | 18 | NA | (56) |
| NT-3 | Plasma | 24 | 24 | The concentration of NT-3 in ASD group was significantly decreased | (45) |
| BLC | Plasma | 25 | 25 | NA | (48) |
| I-309 | Plasma | 25 | 25 | NA | (48) |
| IL-11 | Plasma | 25 | 25 | NA | (48) |
| IL-16 | Plasma | 25 | 25 | NA | (48) |
| Plasma | 28 | 28 | NA | (40) | |
| MDC | Serum | 56 | 32 | The concentration of MDC in ASD group was significantly increased | (46) |
| Serum | 37 | 37 | The concentration of MDC in ASD group was significantly decreased | (49) | |
| TARC | Serum | 56 | 32 | The concentration of TARC in ASD group was significantly increased | (46) |
| IL-3 | Serum | 37 | 37 | The concentration of IL-3 in ASD group was significantly decreased | (49) |
| Plasma | 28 | 28 | NA | (40) | |
| I-TAC | Serum | 21 | 15 | NA | (41) |
| CTACK | Plasma | 28 | 28 | NA | (40) |
| SCF | Plasma | 28 | 28 | NA | (40) |
| SCGF-β | Plasma | 28 | 28 | NA | (40) |
| SDF-1α | Plasma | 28 | 28 | NA | (40) |
| TRAIL | Plasma | 28 | 28 | NA | (40) |
| IL-31 | Serum | 38 | 13 | NA | (55) |
NA, not association.